A Double-blind, Randomized, Single Centre, Vehicle-controlled Study to Evaluate the Safety and Tolerability of a New Topical Formulation Containing 0,09% Imiquimod (Limtop) in Healthy Subjects (Limsafe)
Phase of Trial: Phase I
Latest Information Update: 08 Aug 2016
At a glance
- Drugs Imiquimod (Primary)
- Indications Actinic keratosis; Basal cell cancer; Genital warts
- Focus Adverse reactions
- 30 Apr 2012 Status changed from active, no longer recruiting to completed according to a Moberg Derma media release.
- 02 Apr 2012 New source identified and integrated (ClinicalTrials.gov record NCT01567683).
- 02 Apr 2012 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.